Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENENTECH PUTTING $ 15 MIL. BEHIND GLYCOMED CELL ADHESION R&D

Executive Summary

GENENTECH PUTTING $ 15 MIL. BEHIND GLYCOMED CELL ADHESION R&D to support the Alameda, Calif.-based firm's work in carbohydrate- based therapeutics for inflammatory diseases and cancer under an agreement announced Jan. 7. The deal provides backing from Genentech for an initial three-year period and includes an option for a two-year extension. The funding for Glycomed will be divided between sponsored research and milestone payments. Included in the $ 15 mil. from Genentech is a two-stage $ 7 mil. equity investment in Glycomed described by Genentech as a "significant" stake. Genentech President and CEO Kirk Raab noted in a joint Jan. 7 press release that the agreement represents "the first major collaboration under Genentech's new strategy to accelerate promising development programs by obtaining complementary leading- edge technology in partnership with a development-stage company." The agreement brings together Genentech's work in protein-based cell adhesion molecules and Glycomed's carbohydrate-based cell adhesion research. Under the agreement, Genentech will develop and market carbohydrate-based products for "a broad range of inflammatory diseases in undisclosed areas," the release notes. Glycomed retains rights to "selected inflammatory diseases" and all potential anti-cancer applications. Genentech receives global manufacturing and marketing rights excluding the Far East, for which Glycomed retains all rights. To date, Glycomed has raised $ 26.5 mil. in private funding. In May of 1990, Glycomed completed two rounds of private placements that brought in $ 15.5 mil., including a $ 4 mil. equity investment from Lilly that conferred a 10% stake in Glycomed. The Lilly funding is part of a three-year research agreement announced in January 1990 for the discovery and development of new therapies for the cardiovascular disease, vascular restenosis ("The Pink Sheet" Jan. 15, 1990, In Brief). Glycomed, founded in 1987, is headed by President and CEO Alan Timms, PhD. Timms was with Sandoz from 1962-83 where he concluded his stint as VP-R&D of Sandoz' U.S. subsidiary. He later went to Monsanto where he was general manager of health care R&D and, from 1985-87, he was president of R&D at Searle. Glycomed has a scientific staff of 45. In addition to its research into the use of carbohydrate-based therapies for inflammatory and cardiovascular diseases, the company has several other proprietay projects, including the use of rational drug design techniques to analyze the potential of carbohydrate-based drugs to treat influenza and rotavirus. Glycomed's research partners in academia include Duke University, Washington University of St. Louis, Stanford, Johns Hopkins and Harvard.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel